Two New Members Named to AtriCure’s Board of Directors

AtriCure Inc., an innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors.
 
Telman has spent more than 20 years in senior executive roles at global companies. She is executive vice president and general counsel for Organon, a global healthcare company formed in June 2021 through a spinoff from Merck (known as MSD outside of the United States and Canada) to focus on improving the health of women throughout their lives. Telman helped lead the separation work that created a standalone company serving more than 140 markets with more than 60 medicines and products across a range of therapeutic areas. Going forward she has responsibility for the company’s worldwide legal affairs, compliance, and global environmental health and safety. Before Organon, Telman was general counsel at Sorrento Therapeutics, where she was responsible for mergers and acquisitions, licensing, governance, finance, human resources, regulatory compliance, and legal functions. Previously, she spent four years at Johnson Controls International plc as vice president and general counsel – Building Solutions, North America, and prior to that she held executive roles at Abbott Laboratories and The Boeing Company, and was a partner at Winston and Strawn LLP.
 
“I’m looking forward to joining the board of AtriCure and working with Mike and the rest of the management team to further the company’s mission,” said Telman. “There is an incredible opportunity to treat more patients with innovative therapies and the company has many catalysts for continued growth.”
 
Yuen is currently chief financial officer (CFO) at Penumbra Inc. and is a seasoned executive with more than 20 years of experience within the manufacturing, medical devices, and life science industries. Over the course of her career, she has developed financial and operational expertise at both multi-billion dollar public companies and entrepreneurial start-up ventures. Prior to Penumbra, she was vice president of finance and divisional CFO for the Genetic Science Division for Thermo Fisher Scientific Inc. and was CFO at Mirion Technologies. She has also held various roles at Boston Scientific Corp., GLU Mobile, Lifescan Inc., Picker International, Rockwell Automation, and Eaton Corporation.
 
“I am really excited about the opportunity to join AtriCure’s Board,” said Yuen. “The company is well positioned to capitalize on growth prospects and further the treatment of atrial fibrillation and post-operative pain.”
 
“I am thrilled that Deb and Maggie have agreed to join the AtriCure Board of Directors,” said Michael Carrel, president and CEO. “They have been a part of some incredible companies and have experience in leading by building scale through periods of significant growth. Their expertise in financial matters, compliance, regulatory, legal, commercial initiatives, and corporate strategy will be additive to our company and our team. They are two incredibly talented and capable leaders.”
 
AtriCure Inc. provides technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator Synergy Ablation System is the first medical device to receive U.S. Food and Drug Administration approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.